Osteoarthritis
Musculoskeletal 0 original drugsPhase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q3 2026
Autologous Bone Marrow Aspirate Concentrate
CELL Technologies Inc.
Estimated · stale NCT06216028
Q4 2026
Mesenchymal Stem Cells
Wuxi Cellular Biopharmaceutical Group Ltd.
Estimated · aging NCT06570291
Q3 2027
Pentosan Polysulfate Sodium twice weekly
Paradigm Biopharmaceuticals Ltd.
Estimated · fresh NCT06917404
Q3 2027
CLS2901C (human [allogeneic] chondrocyte sheets)
CellSeed Inc.
Estimated · fresh NCT06549686
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 10 mechanisms across 17 industry trials with a known mechanism of action.
Glucocorticoid receptor
2 trials 1 active 1 sponsor
Nonsteroidal Anti-inflammatory Drug
4 trials 4 sponsors
opioid receptor
2 trials 2 sponsors
MOR/NET
2 trials 2 sponsors
IL1R1
2 trials 1 sponsor
Corticosteroid
1 trials 1 sponsor
Factor Xa Inhibitor
1 trials 1 sponsor
Acetylcholine Release Inhibitor
1 trials 1 sponsor
Partial Opioid Agonist
1 trials 1 sponsor
Opioid Agonist
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
499 industry-sponsored trials across 243 sponsors
Showing 45 of 45 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| ArthroBiologix Inc. | Platelet-rich plasma (PRP) | — | ACTIVE NOT RECRUITING | 2025-12 | NCT04111718 |
| Mather's Pharm. Co., Ltd. | Layla Tab. | — | NOT YET RECRUITING | 2027-12 | NCT07203547 |
| Chong Kun Dang Pharmaceutical | Celecoxib 100 MG | — | COMPLETED | 2017-07-10 | NCT03067194 |
| Lynk Biotechnologies Pte Ltd | Transdermal Glucosamine Cream | — | COMPLETED | 2017-03-10 | NCT03743896 |
| Vedic Lifesciences Pvt. Ltd. | — | — | COMPLETED | 2016-11 | NCT02655939 |
| Propella Therapeutics | Capsaicin Topical Solution | — | COMPLETED | 2016-10 | NCT03124407 |
| Chong Kun Dang Pharmaceutical | Imotun | — | COMPLETED | 2016-10 | NCT01756937 |
| Ache Laboratorios Farmaceuticos S.A. | Motore | — | COMPLETED | 2016-05 | NCT02409381 |
| Daewon Pharmaceutical Co., Ltd. | Pelubiprofen CR 45mg tab. | — | COMPLETED | 2016-03 | NCT02682524 |
| DePuy International | — | — | COMPLETED | 2016-02-17 | NCT01418378 |
| Cellontech Co., Ltd. | Normal saline | — | COMPLETED | 2015-08 | NCT02539095 |
| PMG Pharm Co., Ltd | LAYLA tablet | — | COMPLETED | 2015-05-11 | NCT02049606 |
| Chong Kun Dang Pharmaceutical | Imotun capsule | — | COMPLETED | 2015-04 | NCT01743287 |
| Mundipharma Pte Ltd. | Buprenorphine transdermal patch | — | COMPLETED | 2015-01 | NCT01961271 |
| Mundipharma Pharmaceuticals Sdn. Bhd. | Buprenorphine Transdermal Patch | — | COMPLETED | 2015-01 | NCT02519387 |
| DePuy International | — | — | COMPLETED | 2015-01 | NCT01529099 |
| Sanofi | Hylan G-F 20 | — | COMPLETED | 2013-09 | NCT01586338 |
| SK Chemicals Co., Ltd. | JOINS 200mg | — | COMPLETED | 2013-09 | NCT01293955 |
| Dr. Reddy's Laboratories Limited | NISE | — | COMPLETED | 2013-06 | NCT02922712 |
| Aesculap AG | — | — | COMPLETED | 2013-06 | NCT01496300 |
| Green Cross Corporation | Shinbaro Capsule | — | COMPLETED | 2013-06 | NCT01604239 |
| PMG Pharm Co., Ltd | LAYLA tablet | — | COMPLETED | 2013-06 | NCT01768468 |
| Bioiberica | Chondroitin/Glucosamine (Droglican) | — | COMPLETED | 2013-04 | NCT01425853 |
| Baxter Healthcare Corporation | FLOSEAL Hemostatic Matrix + Standard of care | — | COMPLETED | 2013-01 | NCT01410240 |
| Mundipharma AB | Buprenorphine transdermal patch | — | COMPLETED | 2012-08 | NCT01276431 |
| Gebro Pharma GmbH | Dexibuprofen | — | COMPLETED | 2012-06 | NCT01066676 |
| Tedec-Meiji Farma, S.A. | Hyaluronic acid 5 x 2.5 ml | — | COMPLETED | 2011-10 | NCT01290497 |
| Genzyme, a Sanofi Company | Synvisc-One | — | COMPLETED | 2011-09 | NCT02389452 |
| GSK | Paracetamol | — | COMPLETED | 2011-08-01 | NCT01105936 |
| Exactech | Platelet Rich Plasma | — | COMPLETED | 2011-06 | NCT00826098 |
| Johnson & Johnson Consumer and Personal Products Worldwide | — | — | COMPLETED | 2011-04 | NCT01183624 |
| RS Medical | — | — | COMPLETED | 2010-10 | NCT00701506 |
| Napp Pharmaceuticals Limited | Oxycodone/Naloxone | — | COMPLETED | 2010-03 | NCT00784810 |
| Janssen Pharmaceutica | Fentanyl | opioid receptor | COMPLETED | 2009-09 | NCT01795898 |
| Janssen-Cilag Ltd.,Thailand | TTS-fentanyl | — | COMPLETED | 2009-04 | NCT01774929 |
| Mundipharma Korea Ltd | Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg | — | COMPLETED | 2009-03 | NCT01019265 |
| Janssen-Cilag Ltd.,Thailand | TTS-fentanyl | — | COMPLETED | 2008-11 | NCT01742897 |
| DePuy International | — | — | TERMINATED | 2018-02-08 | NCT01635166 |
| DePuy International | — | — | TERMINATED | 2016-01-01 | NCT01134445 |
| Amp Orthopedics, Inc. | — | — | TERMINATED | 2012-07 | NCT01475604 |
| Amp Orthopedics, Inc. | — | — | TERMINATED | 2012-07 | NCT01457742 |
| Zimmer Biomet | — | — | TERMINATED | 2012-06 | NCT00715026 |
| Pfizer | celecoxib | Nonsteroidal Anti-inflammatory Drug [EPC] | TERMINATED | 2009-06-10 | NCT00484718 |
| Organon and Co | Etoricoxib | — | WITHDRAWN | 2012-08 | NCT01429168 |
| Janssen Scientific Affairs, LLC | Nucynta ER | MOR/NET | WITHDRAWN | 2012-08 | NCT01631513 |
Showing 100 of 169 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Pacira Pharmaceuticals, Inc | ZILRETTA | Glucocorticoid receptor | RECRUITING | 2026-08 | NCT06269705 |
| Saol Therapeutics Inc | SL1002 | — | RECRUITING | 2026-11-30 | NCT07226258 |
| Wuxi Cellular Biopharmaceutical Group Ltd. | Mesenchymal Stem Cells | — | RECRUITING | 2026-12 | NCT06570291 |
| Nature Cell Co. Ltd. | JointStem | — | RECRUITING | 2026-12-30 | NCT04368806 |
| TRB Chemedica | Artrodar | — | RECRUITING | 2026-12-31 | NCT04318041 |
| Doron Therapeutics Inc. | PTP-01 | — | RECRUITING | 2027-04 | NCT07219771 |
| Paradigm Biopharmaceuticals Ltd. | Pentosan Polysulfate Sodium twice weekly | — | RECRUITING | 2027-07 | NCT06917404 |
| CellSeed Inc. | CLS2901C (human [allogeneic] chondrocyte sheets) | — | RECRUITING | 2027-07-31 | NCT06549686 |
| Cellcolabs Clinical SPV Limited | — | — | RECRUITING | 2027-09-27 | NCT07542808 |
| Eli Lilly | Eloralintide | — | RECRUITING | 2028-03 | NCT07353931 |
| Eli Lilly | Orforglipron | — | RECRUITING | 2028-04 | NCT07153471 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-08-14 | NCT07481630 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-08-14 | NCT07509307 |
| Laboratorios Silanes S.A. de C.V. | Celecoxib + Acetaminohen | — | RECRUITING | 2025-10-30 | NCT06863636 |
| R-Bio | JOINTSTEM | — | ACTIVE NOT RECRUITING | 2026-12-23 | NCT04427930 |
| UnicoCell Biomed CO. LTD | ELIXCYTE | — | ACTIVE NOT RECRUITING | 2026-05 | NCT05526001 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-04 | NCT05929066 |
| Lipogems International spa | Saline Injection | — | ACTIVE NOT RECRUITING | 2025-06-23 | NCT06121882 |
| GID BIO, Inc. | — | — | ACTIVE NOT RECRUITING | 2024-12-30 | NCT04440189 |
| Paradigm Biopharmaceuticals USA (INC) | Pentosan Polysulfate Sodium twice weekly | — | ACTIVE NOT RECRUITING | 2024-10-15 | NCT04809376 |
| Kolon TissueGene, Inc. | TG-C | — | ACTIVE NOT RECRUITING | 2024-07-10 | NCT03203330 |
| CELL Technologies Inc. | Autologous Bone Marrow Aspirate Concentrate | — | NOT YET RECRUITING | 2026-08 | NCT06216028 |
| Taisho Pharmaceutical Indonesia | Piroxicam plus Counterirritant (brand name Counterpain® PXM). | — | COMPLETED | 2026-02-12 | NCT07475663 |
| Amzell | AMZ001 Diclofenac gel | — | COMPLETED | 2025-12-22 | NCT06693648 |
| Organogenesis | Amniotic Suspension Allograft | — | COMPLETED | 2025-08-15 | NCT06000410 |
| Grünenthal GmbH | RTX-GRT7039 | — | COMPLETED | 2025-05-15 | NCT05377489 |
| Lipogems International spa | Corticosteroid | — | COMPLETED | 2025-04-09 | NCT05660772 |
| Laboratorios Liomont | Etoricoxib 90 mg + diacerein 50 mg | — | COMPLETED | 2025-03-27 | NCT07549386 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | — | — | COMPLETED | 2025-02-26 | NCT07047196 |
| Grünenthal GmbH | RTX-GRT7039 | — | COMPLETED | 2024-11-18 | NCT05248386 |
| Grünenthal GmbH | RTX-GRT7039 | — | COMPLETED | 2024-08-15 | NCT05449132 |
| Kolon TissueGene, Inc. | TG-C | — | COMPLETED | 2024-03-06 | NCT03291470 |
| Biosplice Therapeutics, Inc. | Lorecivivint | — | COMPLETED | 2024-02-20 | NCT05603754 |
| Techfields Pharma Co. Ltd | X0002 | — | COMPLETED | 2024-01-10 | NCT03081806 |
| Organogenesis | Amniotic Suspension Allograft | — | COMPLETED | 2023-07-30 | NCT04636229 |
| Jiangsu XinChen-Techfields Pharma Co., LTD. | X0002 Spray | — | COMPLETED | 2023-02-06 | NCT05324163 |
| Shin Poong Pharmaceutical Co. Ltd. | SP5M001 inj | — | COMPLETED | 2022-10-25 | NCT06307847 |
| Noven Pharmaceuticals, Inc. | Diclofenac sodium active topical patch | — | COMPLETED | 2022-07-18 | NCT04683627 |
| Pacira Pharmaceuticals, Inc | bupivacaine liposome injectable suspension | — | COMPLETED | 2022-07-11 | NCT05139030 |
| SK Chemicals Co., Ltd. | SKCPT | — | COMPLETED | 2022-05-19 | NCT05930080 |
| Anika Therapeutics, Inc. | Cingal | — | COMPLETED | 2022-05-16 | NCT04231318 |
| Taiwan Liposome Company | TLC599 | — | COMPLETED | 2022-02-03 | NCT04123561 |
| Biosplice Therapeutics, Inc. | Lorecivivint | — | COMPLETED | 2021-09-08 | NCT04385303 |
| Biosplice Therapeutics, Inc. | Lorecivivint | — | COMPLETED | 2021-08-20 | NCT03928184 |
| Bone Therapeutics S.A | JTA-004 | — | COMPLETED | 2021-03-31 | NCT04333160 |
| Taisho Pharmaceutical Co., Ltd. | Esflurbiprofen | — | COMPLETED | 2021-01-11 | NCT03434197 |
| R-Bio | JOINTSTEM | — | COMPLETED | 2020-12-15 | NCT03990805 |
| Regeneron | Fasinumab | — | COMPLETED | 2020-12-01 | NCT02683239 |
| Handok Inc. | Ketoprofen topical | — | COMPLETED | 2020-09-01 | NCT04421911 |
| Regenexx, LLC | Regenexx SD® procedure | — | COMPLETED | 2020-06-30 | NCT02848027 |
| Centrexion Therapeutics | CNTX-4975-05 | — | COMPLETED | 2020-06-11 | NCT03660943 |
| Pfizer | Investigational medical product (IMP) administered in parent study | — | COMPLETED | 2020-06-04 | NCT03031938 |
| Tanabe Pharma Corporation | MT-5547 | — | COMPLETED | 2019-12-14 | NCT03245008 |
| Regeneron | Fasinumab | — | COMPLETED | 2019-12-13 | NCT03304379 |
| Centrexion Therapeutics | CNTX-4975-05 | — | COMPLETED | 2019-11-22 | NCT03429049 |
| Pacira Pharmaceuticals, Inc | FX006 32 mg | — | COMPLETED | 2019-11-08 | NCT03529942 |
| Centrexion Therapeutics | CNTX-4975-05 | — | COMPLETED | 2019-10-22 | NCT03661996 |
| Regeneron | Fasinumab | — | COMPLETED | 2019-09-09 | NCT03161093 |
| Pfizer | Investigational Medical Product (IMP) administered in parent study | — | COMPLETED | 2019-07-15 | NCT02674386 |
| Amzell | AMZ001 | — | COMPLETED | 2019-07-09 | NCT03691844 |
| Yooyoung Pharmaceutical Co., Ltd. | YYD302 2ml | — | COMPLETED | 2019-06-14 | NCT03561779 |
| Eurofarma Laboratorios S.A. | Glucosamine and chondroitin sulfate combination (Eurofarma) | — | COMPLETED | 2019-05-10 | NCT02830919 |
| Genzyme, a Sanofi Company | Placebo | — | COMPLETED | 2019-01-28 | NCT03190369 |
| Pfizer | NSAID | — | COMPLETED | 2018-10-05 | NCT02528188 |
| Anika Therapeutics, Inc. | Triamcinolone Hexacetonide | — | COMPLETED | 2018-07-30 | NCT03390036 |
| Pacira Pharmaceuticals, Inc | FX006 32 mg | — | COMPLETED | 2018-07-19 | NCT03046446 |
| IBSA Institut Biochimique SA | — | — | COMPLETED | 2018-06-27 | NCT03200288 |
| TRB Chemedica International SA | Diacerein | — | COMPLETED | 2018-06-26 | NCT02688400 |
| Pfizer | Tanezumab | — | COMPLETED | 2018-06-08 | NCT02709486 |
| Bone Therapeutics S.A | JTA-004 intra-articular injection | — | COMPLETED | 2018-04-27 | NCT02740231 |
| Cartiva, Inc. | — | — | COMPLETED | 2018-04-27 | NCT02978573 |
| Anika Therapeutics, Inc. | Triamcinolone Hexacetonide | — | COMPLETED | 2018-04-23 | NCT03191903 |
| Ampio Pharmaceuticals. Inc. | 4 mL injection of Ampion | — | COMPLETED | 2017-12-07 | NCT03182686 |
| Mylan Pharmaceuticals Private Limited | Diclofenac sodium gel 1% | — | COMPLETED | 2017-12-05 | NCT03172780 |
| Pfizer | Tanezumab 2.5 mg | — | COMPLETED | 2017-12-05 | NCT02697773 |
| Delivra, Inc. | — | — | COMPLETED | 2017-11 | NCT02193711 |
| Huons Co., Ltd. | Humia inj. | — | COMPLETED | 2017-10 | NCT02893098 |
| Apimeds, Inc. | Apitox, purified honeybee toxin, lyophilized in saline | — | COMPLETED | 2016-11 | NCT01112722 |
| Johnson & Johnson | Fulranumab 1 mg | — | COMPLETED | 2016-10-10 | NCT02289716 |
| Johnson & Johnson | Fulranumab 1 mg | — | COMPLETED | 2016-09-19 | NCT02301234 |
| Johnson & Johnson | Fulranumab 1 mg | — | COMPLETED | 2016-09-16 | NCT02336685 |
| Johnson & Johnson | Fulranumab 1 mg | — | COMPLETED | 2016-09-15 | NCT02336698 |
| Thuasne | — | — | COMPLETED | 2016-07 | NCT02021136 |
| Cartiva, Inc. | — | — | COMPLETED | 2016-07 | NCT00969969 |
| Ampio Pharmaceuticals. Inc. | 4 mL injection of AMPION™ | — | COMPLETED | 2016-06 | NCT02556710 |
| Akorn, Inc. | Diclofenac Sodium Gel 1% | — | COMPLETED | 2016-04 | NCT02913521 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2016-03 | NCT02335346 |
| Glenmark Pharmaceuticals Ltd. India | Diclofenac Sodium gel, 1% | — | COMPLETED | 2016-03 | NCT02596451 |
| Regeneron | REGN475 | — | COMPLETED | 2016-03 | NCT02447276 |
| Pacira Pharmaceuticals, Inc | FX006 | — | COMPLETED | 2016-01 | NCT02357459 |
| Carbylan Therapeutics, Inc. | Triamcinolone Acetonide | Corticosteroid [EPC] | COMPLETED | 2015-12 | NCT02022930 |
| IBSA Institut Biochimique SA | chondroitin sulfate | — | COMPLETED | 2015-10-19 | NCT02079727 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2015-06 | NCT02248480 |
| Medipost Co Ltd. | CARTISTEM | — | COMPLETED | 2015-05 | NCT01626677 |
| LG Life Sciences | LBSA0103 (BDDE cross-linked sodium hyaluronate gel) | — | COMPLETED | 2015-05 | NCT02122601 |
| Ampio Pharmaceuticals. Inc. | 4 mL injection of Ampion | — | COMPLETED | 2015-04 | NCT02242435 |
| Anika Therapeutics, Inc. | — | — | COMPLETED | 2015-04 | NCT02381652 |
| Eli Lilly | Duloxetine | — | COMPLETED | 2015-03 | NCT01931475 |
| Hanlim Pharm. Co., Ltd. | Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks | — | COMPLETED | 2014-10-15 | NCT01768520 |
| Amneal Pharmaceuticals, LLC | Diclofenac Sodium Topical Gel, 1% | — | COMPLETED | 2014-10 | NCT02121002 |
Showing 100 of 205 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Sclnow Biotechnology Co., Ltd. | Low dose mesenchymal stem cells | — | RECRUITING | 2026-06-30 | NCT03383081 |
| 4Moving Biotech | 4P004 | — | RECRUITING | 2026-07 | NCT07225829 |
| Glaceum | Vutiglabridin | — | RECRUITING | 2026-07-31 | NCT06845553 |
| VivaTech International, Inc. | [StroMed + platelet rich plasma (PRP)] | — | RECRUITING | 2026-08 | NCT02844764 |
| VivaTech International, Inc. | [StroMed + platelet rich plasma (PRP)] | — | RECRUITING | 2026-08 | NCT02844751 |
| VivaTech International, Inc. | [StroMed + platelet rich plasma (PRP)] | — | RECRUITING | 2026-08 | NCT02844738 |
| KeyBioscience AG | KBP-336 | — | RECRUITING | 2026-11 | NCT06833749 |
| TBF Genie Tissulaire | SclerFIX-IP | — | RECRUITING | 2026-12 | NCT06038331 |
| Enlivex Therapeutics Ltd. | Allocetra | — | RECRUITING | 2027-02 | NCT07580716 |
| Eli Lilly | LY3016859 ISA | — | RECRUITING | 2027-04 | NCT05986292 |
| Ageless Biotech, Inc. | OA-SYS | — | RECRUITING | 2028-03-31 | NCT06485843 |
| TBF Genie Tissulaire | SclerFIX-IP | — | RECRUITING | 2026-01 | NCT06034262 |
| Medipost Co Ltd. | SMUP-IA-01(low-dose) | — | ACTIVE NOT RECRUITING | 2027-03-20 | NCT06798727 |
| OrthoTrophix, Inc | TPX-100 200mg, Once weekly for 4 weeks | — | ACTIVE NOT RECRUITING | 2027-03-25 | NCT06865079 |
| Pacira Pharmaceuticals, Inc | Enekinragene Inzadenovec (PCRX-201) | — | ACTIVE NOT RECRUITING | 2032-07 | NCT06884865 |
| Enlivex Therapeutics Ltd. | Allocetra | — | ACTIVE NOT RECRUITING | 2026-03-15 | NCT06233474 |
| ICM Biotech Australia Pty Ltd. | Placebo | — | ACTIVE NOT RECRUITING | 2026-03 | NCT04875754 |
| Bioventus LLC | PTP-001 | — | ACTIVE NOT RECRUITING | 2022-10-31 | NCT05100225 |
| BioIntegrate | Umbilical Cord-derived Wharton's Jelly | — | NOT YET RECRUITING | 2026-06-01 | NCT04711304 |
| Kolon TissueGene, Inc. | TG-C | — | NOT YET RECRUITING | 2026-10 | NCT05276011 |
| Nuwacell Biotechnologies Co., Ltd. | NCR100 | — | NOT YET RECRUITING | 2026-11-30 | NCT06741098 |
| Addpharma Inc. | AD-211-L | — | NOT YET RECRUITING | 2027-03 | NCT07550231 |
| Nova Vita Laboratory | NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF) | — | NOT YET RECRUITING | 2027-04-01 | NCT06606561 |
| TricelX Inc. | Mesenchymal Stem Cell Injection | — | NOT YET RECRUITING | 2027-05 | NCT07487766 |
| ICM Co. Ltd. | — | — | NOT YET RECRUITING | 2027-05-15 | NCT05454566 |
| TBF Genie Tissulaire | — | — | NOT YET RECRUITING | 2028-03 | NCT07435571 |
| CarthroniX, Inc. | CX-011 | — | NOT YET RECRUITING | 2028-10-30 | NCT07308834 |
| Peptinov SAS | PPV-06 | — | NOT YET RECRUITING | 2028-12 | NCT06605963 |
| Celltex Therapeutics Corporation | Celltex- AdMSCs | — | NOT YET RECRUITING | 2024-08-01 | NCT04448106 |
| Synartro AB | SYN321 | — | COMPLETED | 2026-02-02 | NCT06989645 |
| Chong Kun Dang Pharmaceutical | Reference Drug | — | COMPLETED | 2025-10-28 | NCT06954766 |
| Xindu Pty Ltd | XSTEM-OA | — | COMPLETED | 2025-06-18 | NCT05344157 |
| BioTissue Holdings, Inc | TTAX03 | — | COMPLETED | 2025-03-07 | NCT05079035 |
| Novartis | RHH646 | — | COMPLETED | 2025-02-24 | NCT05816395 |
| Novartis | DFV890 | — | COMPLETED | 2024-12-14 | NCT04886258 |
| Novartis | LRX712 | — | COMPLETED | 2024-08-08 | NCT04097379 |
| PT. Prodia Stem Cell Indonesia | Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome | — | COMPLETED | 2024-07-08 | NCT04314661 |
| Levicept | LEVI-04 | — | COMPLETED | 2024-05-20 | NCT05618782 |
| TBF Genie Tissulaire | MENISC-T | — | COMPLETED | 2024-02-08 | NCT05250726 |
| LG Chem | LG00034053 | — | COMPLETED | 2023-12-19 | NCT05237752 |
| Taiwan Bio Therapeutics Inc. | Bone marrow mesenchymal stem cells | — | COMPLETED | 2023-12-10 | NCT05027581 |
| Taiwan Liposome Company | TLC599 | — | COMPLETED | 2023-11-07 | NCT03754049 |
| Medipost Co Ltd. | SMUP-IA-01(low dose) | — | COMPLETED | 2023-10-17 | NCT05182034 |
| OliPass Corporation | OLP-1002 | — | COMPLETED | 2023-09-07 | NCT05216341 |
| AstraZeneca | MEDI7352 | — | COMPLETED | 2023-08-16 | NCT04675034 |
| Apsen Farmaceutica S.A. | S (+) - Ibuprofen | — | COMPLETED | 2023-06-30 | NCT04637529 |
| Eli Lilly | LY3857210 | — | COMPLETED | 2023-06-05 | NCT05620563 |
| Eupraxia Pharmaceuticals Inc. | EP-104IAR 25 mg | — | COMPLETED | 2023-05-17 | NCT04120402 |
| BUZZZ Pharmaceuticals Limited | G001 Topical Gel | — | COMPLETED | 2023-01-04 | NCT05007808 |
| ZetrOZ, Inc. | 1% Diclofenac Topical Gel | — | COMPLETED | 2022-12-01 | NCT05050448 |
| Novartis | LNA043 | — | COMPLETED | 2022-09-06 | NCT03275064 |
| Eli Lilly | LY3526318 | — | COMPLETED | 2022-06-06 | NCT05080660 |
| Sun Pharmaceutical Industries Limited | MM-II dose I | — | COMPLETED | 2022-05-04 | NCT04506463 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. | GXCPC1 | — | COMPLETED | 2022-04-27 | NCT03943576 |
| Xalud Therapeutics, Inc. | XT-150 | — | COMPLETED | 2022-04-26 | NCT04124042 |
| MiMedx Group, Inc. | Micronized dHACM | — | COMPLETED | 2022-04-19 | NCT03485157 |
| Cytopeutics Sdn. Bhd. | Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) | — | COMPLETED | 2022-03-21 | NCT05016011 |
| Eli Lilly | LY3556050 | — | COMPLETED | 2021-10-21 | NCT04627038 |
| AKL Research and Development | APPA | — | COMPLETED | 2021-09-30 | NCT04657926 |
| Shanghai AbelZeta Ltd. | Mesenchymal progenitor cells | — | COMPLETED | 2021-06-30 | NCT04208646 |
| Eli Lilly | LY3016859 | — | COMPLETED | 2021-04-22 | NCT04456686 |
| CARE ARTHRITIS LTD. | Adalimumab 40 mg | — | COMPLETED | 2021-03 | NCT02471118 |
| R-Bio | Jointstem | — | COMPLETED | 2020-12-09 | NCT03509025 |
| Biosplice Therapeutics, Inc. | SM04690 | — | COMPLETED | 2020-09-18 | NCT03727022 |
| Galapagos NV | GLPG1972 | — | COMPLETED | 2020-07-14 | NCT03595618 |
| Unity Biotechnology, Inc. | UBX0101 | — | COMPLETED | 2020-05-20 | NCT04129944 |
| Yooyoung Pharmaceutical Co., Ltd. | Celecoxib 200mg | — | COMPLETED | 2020-05-12 | NCT03850587 |
| Regeneron | Fasinumab | — | COMPLETED | 2020-01-30 | NCT03691974 |
| Swisse Wellness Pty Ltd | — | — | COMPLETED | 2019-12-30 | NCT03483090 |
| Antibe Therapeutics Inc. | ATB-346 low dose | — | COMPLETED | 2019-12-29 | NCT03978208 |
| Tianjin XinChen-Techfields Pharma Co., LTD. | X0002 Spray | — | COMPLETED | 2019-10-21 | NCT03691818 |
| Pacira Pharmaceuticals, Inc | FX006 32 mg | — | COMPLETED | 2019-10-11 | NCT04065074 |
| Noven Pharmaceuticals, Inc. | Diclofenac Sodium Active Topical Patch 1 | — | COMPLETED | 2019-09-25 | NCT03277066 |
| Bayer | Naproxen Sodium (Aleve, BAY117031) | — | COMPLETED | 2019-06-14 | NCT03570554 |
| Propella Therapeutics | CGS-200-1 | — | COMPLETED | 2018-10-14 | NCT03528369 |
| Pacira Pharmaceuticals, Inc | FX006 32 mg | — | COMPLETED | 2018-10-09 | NCT03382262 |
| Seikagaku Corporation | — | — | COMPLETED | 2018-08-17 | NCT03209362 |
| Taiwan Liposome Company | TLC599 LD group | — | COMPLETED | 2018-07-04 | NCT03005873 |
| UnicoCell Biomed CO. LTD | Elixcyte 8 ml | — | COMPLETED | 2018-07 | NCT02784964 |
| Biosplice Therapeutics, Inc. | SM04690 | — | COMPLETED | 2018-04-30 | NCT03122860 |
| Pacira Pharmaceuticals, Inc | FX006 32 mg | — | COMPLETED | 2018-03-14 | NCT03378076 |
| Nature Cell Co. Ltd. | JointStem | — | COMPLETED | 2018-03-12 | NCT02674399 |
| New Jersey Regenerative Institute, LLC | — | — | COMPLETED | 2018-03-01 | NCT03714659 |
| Symic OA Co. | — | — | COMPLETED | 2017-12-18 | NCT03231280 |
| GSK | GSK3196165 | — | COMPLETED | 2017-11-29 | NCT02683785 |
| Medivir | MIV-711 | — | COMPLETED | 2017-11-28 | NCT03037489 |
| Yooyoung Pharmaceutical Co., Ltd. | YYD302 2ml | — | COMPLETED | 2017-09 | NCT02965495 |
| Astellas Pharma Europe B.V. | ASP7962 | — | COMPLETED | 2017-08-28 | NCT02611466 |
| OrthoTrophix, Inc | TPX-100 200 mg 4 times weekly for 4 weeks | — | COMPLETED | 2017-08 | NCT02837900 |
| Genzyme, a Sanofi Company | GZ389988 | — | COMPLETED | 2017-06-28 | NCT02845271 |
| KGK Science Inc. | — | — | COMPLETED | 2017-06-19 | NCT02604381 |
| Yuhan Corporation | YH23537 | — | COMPLETED | 2017-05-24 | NCT02759198 |
| Medivir | MIV-711 | — | COMPLETED | 2017-05-23 | NCT02705625 |
| Cara Therapeutics, Inc. | CR845 tablet 1 mg | — | COMPLETED | 2017-05 | NCT02944448 |
| Biosplice Therapeutics, Inc. | SM04690 | — | COMPLETED | 2017-04-20 | NCT02536833 |
| Symic OA Co. | — | — | COMPLETED | 2017-02 | NCT02802709 |
| Taiwan Liposome Company | TLC599 | — | COMPLETED | 2016-11 | NCT02803307 |
| R-Bio | JOINTSTEM | — | COMPLETED | 2016-11 | NCT02658344 |
| Pacira Pharmaceuticals, Inc | FX006 32 mg | — | COMPLETED | 2016-10 | NCT02762370 |
| Centrexion Therapeutics | CNTX-4975 | — | COMPLETED | 2016-10 | NCT02558439 |
Showing 80 of 80 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Shandong Suncadia Medicine Co., Ltd. | HRS-2129 Tablet | — | RECRUITING | 2026-08 | NCT07351968 |
| Avidence Therapeutics | AVD275 Intra-articular Injection | — | RECRUITING | 2026-12 | NCT07338266 |
| Scarcell Therapeutics S.A.S. | allogeneic engineered Gingival Fibroblasts (aeGF) | — | RECRUITING | 2027-02-01 | NCT06690710 |
| Belief BioMed (Beijing) Co., Ltd | BBM-A101 | — | RECRUITING | 2027-12-30 | NCT07198555 |
| ZetrOZ, Inc. | 2.5% Diclofenac Patches | — | RECRUITING | 2026-05-01 | NCT05254574 |
| iN Therapeutics Co., Ltd. | iN1011-N17 HCl Suspension (Part 1) | — | RECRUITING | 2024-07-29 | NCT06218784 |
| Anterogen Co., Ltd. | ANT-301 | — | ACTIVE NOT RECRUITING | 2026-05-15 | NCT06539429 |
| Genascence Corporation | transient immune-modulation | — | ACTIVE NOT RECRUITING | 2025-04-08 | NCT05835895 |
| Pacira Pharmaceuticals, Inc | FX201 | — | ACTIVE NOT RECRUITING | 2023-11-28 | NCT04119687 |
| Rion Inc. | PEP | — | NOT YET RECRUITING | 2025-11-01 | NCT06463132 |
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 5% ASKC200 | — | NOT YET RECRUITING | 2025-04 | NCT06614608 |
| Frontier Biotechnologies Inc. | Loxoprofen Sodium Patches(reference product) | — | NOT YET RECRUITING | 2024-08 | NCT06510413 |
| Contineum Therapeutics | PIPE-791 | — | COMPLETED | 2026-01-20 | NCT06810245 |
| Sanofi | SAR446959 | — | COMPLETED | 2025-12-18 | NCT06704932 |
| Cytonics Corporation | CYT-108, a recombinant protease inhibitor | — | COMPLETED | 2025-03-15 | NCT06263270 |
| 4Moving Biotech | 4P-004 | — | COMPLETED | 2023-10-31 | NCT05419856 |
| iN Therapeutics Co., Ltd. | iN1011-N17 | — | COMPLETED | 2023-10-08 | NCT05496205 |
| Eccogene | ECC0509 | — | COMPLETED | 2023-07-22 | NCT05012423 |
| Peptinov SAS | PPV-06 10 μg | — | COMPLETED | 2023-02-28 | NCT04447898 |
| Noven Pharmaceuticals, Inc. | HP-5000 Topical Patch | — | COMPLETED | 2022-03-08 | NCT04882319 |
| ZYUS Life Sciences Inc. | Trichomylin for SAD | — | COMPLETED | 2022-02-18 | NCT04867057 |
| AstraZeneca | MEDI7352 | — | COMPLETED | 2021-12-02 | NCT04770428 |
| Levicept | LEVI-04 | — | COMPLETED | 2021-03-31 | NCT03227796 |
| Orient Europharma Co., Ltd. | 2ccPA | — | COMPLETED | 2021-03-22 | NCT04229394 |
| OliPass Australia Pty Ltd | A: OLP-1002 | — | COMPLETED | 2020-12-22 | NCT04677933 |
| Novartis | LNA043 | — | COMPLETED | 2020-12-10 | NCT04564053 |
| Medipost Co Ltd. | SMUP-IA-01(low-dose) | — | COMPLETED | 2020-11-12 | NCT04037345 |
| Unity Biotechnology, Inc. | UBX0101 | — | COMPLETED | 2020-09-18 | NCT04229225 |
| Daewon Pharmaceutical Co., Ltd. | DW1809-T2 | — | COMPLETED | 2020-09-08 | NCT05214690 |
| Daewon Pharmaceutical Co., Ltd. | DW1809 | — | COMPLETED | 2020-09-07 | NCT05214677 |
| Sorrento Therapeutics, Inc. | Resiniferatoxin | — | COMPLETED | 2020-04-13 | NCT03542838 |
| Regeneron | Fasinumab AI | — | COMPLETED | 2020-01-15 | NCT03491904 |
| Shan May Yong | — | — | COMPLETED | 2019-10-31 | NCT04483024 |
| Xalud Therapeutics, Inc. | XT-150 | — | COMPLETED | 2019-10-30 | NCT03769662 |
| EMO Biomedicine Corporation | RegStem | — | COMPLETED | 2019-08-31 | NCT03007576 |
| Merck KGaA, Darmstadt, Germany | M6495 | — | COMPLETED | 2019-07-31 | NCT03583346 |
| Xalud Therapeutics, Inc. | XT-150 | — | COMPLETED | 2019-07-19 | NCT03477487 |
| Xalud Therapeutics, Inc. | XT-150 | — | COMPLETED | 2019-03-31 | NCT03282149 |
| Unity Biotechnology, Inc. | UBX0101 | — | COMPLETED | 2019-03-29 | NCT03513016 |
| Novartis | LRX712 | — | COMPLETED | 2019-03-26 | NCT03355196 |
| Steminent Biotherapeutics Inc. | Adipose-Derived Mesenchymal Stem Cells | — | COMPLETED | 2019-01-31 | NCT02544802 |
| Centrexion Therapeutics | CNTX-4975-05 | — | COMPLETED | 2018-09-06 | NCT03576508 |
| Centrexion Therapeutics | CNTX-4975-05 (trans-capsaicin) | — | COMPLETED | 2018-07-27 | NCT03472677 |
| Shanghai AbelZeta Ltd. | Mesenchymal progenitor cells | — | COMPLETED | 2018-03 | NCT02641860 |
| Novartis | LNA043 | — | COMPLETED | 2018-02-07 | NCT02491281 |
| Eupraxia Pharmaceuticals Inc. | EP-104IAR | — | COMPLETED | 2017-12-28 | NCT02609126 |
| Galapagos NV | GLPG1972 cohort 1 | — | COMPLETED | 2017-10-25 | NCT03311009 |
| Regenexx, LLC | Lavage with Platelet Poor Plasma (PPP) | — | COMPLETED | 2017-06-30 | NCT03120988 |
| Grünenthal GmbH | Lopain | — | COMPLETED | 2017-06 | NCT02566564 |
| Tianjin XinChen-Techfields Pharma Co., LTD. | X0002 | — | COMPLETED | 2017-03 | NCT02794740 |
| Ampio Pharmaceuticals. Inc. | AMPION™ | — | COMPLETED | 2016-11 | NCT02762760 |
| Zimmer Biomet | APS | — | COMPLETED | 2016-10 | NCT02262364 |
| Shenzhen Hornetcorn Bio-technology Company, LTD | Human umbilical cord mesenchymal stem cells | — | COMPLETED | 2016-07 | NCT02291926 |
| Galapagos NV | GLPG1972 600 mg oral solution fasted | — | COMPLETED | 2016-07 | NCT02851485 |
| Genzyme, a Sanofi Company | GZ389988 | — | COMPLETED | 2016-07 | NCT02424942 |
| Ono Pharmaceutical Co., Ltd. | ONO-4474 Part A1 | — | COMPLETED | 2016-04 | NCT02454387 |
| Biosplice Therapeutics, Inc. | SM04690, 0.03mg/2mL | — | COMPLETED | 2015-09 | NCT02095548 |
| Bioheart, Inc. | Intra-articular injection of SVF plus PRP | — | COMPLETED | 2014-12-30 | NCT03089762 |
| Boehringer Ingelheim | BI 1026706 | — | COMPLETED | 2014-10-01 | NCT02126826 |
| Galderma R&D | Botulinum toxin | — | COMPLETED | 2014-07 | NCT02139319 |
| AbbVie (prior sponsor, Abbott) | ABT-981 | — | COMPLETED | 2013-10 | NCT01668511 |
| Sanofi | SAR113945 | — | COMPLETED | 2012-09 | NCT01511549 |
| Sanofi | SAR113945 | — | COMPLETED | 2012-08 | NCT01463488 |
| Stryker Biotech | Bone morphogenetic protein 7 | — | COMPLETED | 2011-10 | NCT01133613 |
| Merck | — | — | COMPLETED | 2011-06 | NCT00917696 |
| Sanofi | SAR113945 | — | COMPLETED | 2011-02 | NCT01113333 |
| Abbott | PG110 | — | COMPLETED | 2011-01 | NCT00941746 |
| Merck KGaA, Darmstadt, Germany | AS902330 | — | COMPLETED | 2010-10 | NCT01033994 |
| Pfizer | tanezumab | — | COMPLETED | 2010-09 | NCT01030640 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | JNJ-39439335; Placebo; Naproxen | — | COMPLETED | 2010-06 | NCT00933582 |
| Mundipharma (China) Pharmaceutical Co. Ltd | buprenorphine | Partial Opioid Agonist [EPC] | COMPLETED | 2010-03 | NCT01643759 |
| Pfizer | Oxycodone | Opioid Agonist [EPC] | COMPLETED | 2009-03 | NCT00743587 |
| Merck | Naproxen | Nonsteroidal Anti-inflammatory Drug [EPC] | COMPLETED | 2008-11 | NCT00772967 |
| NicOx | naproxcinod 375 mg bid | — | COMPLETED | 2008-09 | NCT00662896 |
| NicOx | naproxcinod 375 mg -750 mg -1125 mg bid | — | COMPLETED | 2008-08 | NCT00662610 |
| Johnson & Johnson | JNJ-39439335 | — | COMPLETED | — | NCT01343303 |
| Boehringer Ingelheim | BI 113823 | — | TERMINATED | 2011-01 | NCT01207973 |
| AstraZeneca | MEDI-578 | — | TERMINATED | 2010-09 | NCT01072591 |
| VIVEX Biologics, Inc. | AlloGen Liquid | — | WITHDRAWN | 2022-03-01 | NCT04835389 |
| Clinica Santa Clarita, Mexico | Human allogeneic mesenchymal bone marrow derived stem cells | — | WITHDRAWN | 2020-04 | NCT03602872 |
Novel Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (11 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
VYSCOXA
CARWIN PHARM ASSOC
T3 2025
COXANTO
SOLUBIOMIX
T3 2023
ELYXYB
SCILEX PHARMS
T3 2020
ZILRETTA
PACIRA PHARMS INC
T5 2017
CELEBREX
UPJOHN
T1 1998
ARTHROTEC
Pfizer
T4 1997
NAPRELAN
TWI PHARMS
T3 1996
EC-NAPROSYN
ATNAHS PHARMA US
T3 1994
DAYPRO
Pfizer
T1 1992
FELDENE
Pfizer
T1 1982
NAPROSYN
ATNAHS PHARMA US
T1 1976
Drug Targets
Generic Drugs (9 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs